472. Evaluation of Re-Administration of a Recombinant Adeno-Associated Vector Expressing Acid-Alpha-Glucosidase (rAAV9-DES-hGAA) in Pompe Disease: Preclinical to Clinical Planning
Manuela Corti(University of Florida), Barry J. Byrne(University of Florida), Thomas J. Conlon(Adelson Foundation), Janet M. Benson(Lovelace Respiratory Research Institute), Brian Cleaver(University of Florida), Roland W. Herzog(Heidelberg University), Gensheng Wang(Lovelace Respiratory Research Institute), Nathalie Clément(University of Florida), Alice F. Tarantal(University of California, Davis), Kaitlyn J. Faris(University of Florida)
Cited by 0
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Literature review of Florida red tide: implications for human health effects
|Harmful Algae|2003|379
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322